Kiri Granger
Co-Founder & Chief Scientific Officer Monument Therapeutics
Seminars
Wednesday 1st April 2026
Translating Neurological Biomarkers into Predictive & Prognostic Diagnostic Tools for Therapy Qualification
2:20 pm
- How to define the unmet need for biomarkers in neurological diseases so that patient eligibility for novel therapies is better established and trial recruitment becomes more efficient?
- How to leverage diagnostic platforms such as mass spectrometry or high-sensitivity immunoassays so that biomarker measurements become more standardised and comparable across trials, enabling broader clinical adoption?
- What is the regulatory pathway in Europe for neurological biomarkers compared with oncology?
